HC Wainwright Predicts Weaker Earnings for DBV Technologies

Key Points

• HC Wainwright has lowered its Q3 2025 earnings per share estimate for DBV Technologies to ($1.65), down from the previous estimate of ($1.45), while maintaining a "Buy" rating with a target price of $16.00.
• DBV Technologies reported a quarterly loss of ($1.55) EPS, significantly missing analysts' consensus estimates, with a revenue of $1.74 million compared to expected $0.64 million.
• The company's stock recently dropped 9.5% and has a market capitalization of $233.09 million, with a consensus rating of "Moderate Buy" and target price of $14.75.

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - HC Wainwright dropped their Q3 2025 earnings per share estimates for shares of DBV Technologies in a research report issued to clients and investors on Wednesday, July 30th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($1.65) per share for the quarter, down from their prior estimate of ($1.45). HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for DBV Technologies' current full-year earnings is ($7.05) per share. HC Wainwright also issued estimates for DBV Technologies' Q4 2025 earnings at ($1.70) EPS, FY2025 earnings at ($6.30) EPS, FY2026 earnings at ($6.25) EPS, FY2027 earnings at ($5.90) EPS, FY2028 earnings at ($3.40) EPS and FY2029 earnings at $0.75 EPS.

A number of other brokerages have also issued reports on DBVT. Lifesci Capital raised DBV Technologies to a "strong-buy" rating in a research report on Thursday, June 26th. JMP Securities reaffirmed a "market outperform" rating and set a $21.00 target price on shares of DBV Technologies in a research report on Thursday, June 26th. Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a research report on Tuesday, May 27th. Wall Street Zen lowered DBV Technologies from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. Finally, The Goldman Sachs Group raised DBV Technologies to a "sell" rating and set a $7.25 target price on the stock in a research report on Thursday, May 29th. Two investment analysts have rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, DBV Technologies has a consensus rating of "Moderate Buy" and a consensus target price of $14.75.

DBV Technologies Stock Down 9.5%

Shares of DBV Technologies stock opened at $8.51 on Friday. The stock's fifty day moving average is $9.48 and its 200-day moving average is $7.38. The firm has a market capitalization of $233.09 million, a PE ratio of -1.78 and a beta of -0.59. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $12.78.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.34). The company had revenue of $1.74 million for the quarter, compared to analyst estimates of $0.64 million. DBV Technologies had a negative return on equity of 287.15% and a negative net margin of 3,220.49%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies at the end of the most recent quarter. Hedge funds and other institutional investors own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.